Streamline R&D with actionable immunogenicity data.

Now offering a solution designed for monoclonal antibody developers seeking an even easier and faster immunogenicity risk assessment to characterize lead candidates! ISPRI Quantify™ provides a profile of immunogenic risk for a lead candidate with results that can guide your R&D strategy, allowing you to save time and money on downstream in vitro and in vivo immunogenicity studies.

With this “just the facts” analysis, you’ll receive a rapid, precise, and holistic immunogenicity overview. The assessment compiles what EpiVax experts consider to be the most critical scores available from our in silico toolkit to enable an accurate prediction of immunogenic potential, including details on sequence-level T cell epitope and “humanness” scoring. These scores are ranked against mAbs of known immunogenicity for easy benchmarking (Figure 1), a high-level “T cell epitope content breakdown” (Figure 2) is provided, as well as T cell epitope maps to give regional immunogenicity insights (Figure 3) to classify the number of regulatory, potentially tolerated, and foreign epitopes in your sequence (key considerations for the most accurate risk assessment).

For a deeper clinical perspective, clients may opt for Quantify Plus™, which adds additional context by considering the influence of product, patient, and treatment-related factors on immunogenicity. This enhanced assessment provides a more holistic view of immunogenicity risk to better guide your immunogenicity risk mitigation strategy as you move forward in development.

ISPRI Quantify™ will empower you to navigate the complexities of immunogenicity risk swiftly and confidently.